Subgroup analyses showed that the protective effect of JAKi therapy against uveitis was more pronounced in older adults, White individuals, and patients with elevated inflammatory markers (CRP ≥3 mg/L or ESR ≥20 mm/h). The gene discussed is CRP; the disease is uveitis.